FIGURE 3.

RNA expression of sgp130 variants. A, schematic of the exon-intron structure of the 5′ beginning of all gp130 transcripts and the individual 3′ ends of the three soluble forms of gp130, adapted from Ref. 40. Full-length sgp130 results from an exon insertion, whereas sgp130-RAPS is produced after an exon deletion. sgp130-E10 is produced when an alternative polyadenylation site after exon 10 is used. Binding sites of oligonucleotides used to specifically amplify the different transcripts are indicated by arrows. B, RNA expression of the total gp130 transcripts and the three soluble forms of gp130 was analyzed in different human primary cell types (T cells, B cells, monocytes, macrophages, and granulocytes) as well as in human cell lines (Huh7, HepG2, Fh-hTERT, and HEK293) as indicated. Amplification of β-actin was used as a control. One representative experiment of three independent experiments with similar outcomes is shown.